Paeds Vivas · infectious-diseases
Tuberculosis in children — branching viva
Branching viva on the exposure-infection-disease spectrum, the age-and-immunity pathophysiology, symptom-and-contact assessment, chest radiograph and Xpert MTB/RIF workup, weight-based treatment (4-month SHINE regimen for non-severe disease, 6-month for severe), tuberculosis preventive treatment, the emergency recognition of tuberculous meningitis, and notification, contact tracing and source-case finding.
On this page
Study tools
Target exams
Viva \u2014 Branching structured oral
Stem. A four-year-old boy is brought in thin, with a cough and intermittent fever for six weeks. His uncle was diagnosed with smear-positive pulmonary tuberculosis two weeks ago, and his chest radiograph shows right paratracheal lymph-node enlargement. [1]
Branch 1 \u2014 Classification on the spectrum
Examiner: Where does this child sit on the TB spectrum, and why does that matter? [1]
Model answer. He has TB disease, not exposure or TB infection alone, because he has both symptoms (six weeks of cough and fever with thinness) and a compatible radiograph (paratracheal lymph-node enlargement). The spectrum \u2014 exposure, TB infection (the child is well but infected), TB disease (symptoms and/or radiological signs) \u2014 matters because it dictates everything that follows: observe, treat infection, or treat disease. I classify his disease as intrathoracic, and by severity as non-severe (lymph-node, non-cavitary, smear-negative pattern). [1] [2]
Examiner follow-up: His uncle is the source case. Why is the contact the most useful piece of information here? [1]
Model answer. The contact history is often the most specific bedside finding in childhood TB, because it establishes recent exposure to a known infectious adult and lifts the pre-test probability of disease substantially. It also lets me obtain the source case's drug-susceptibility result, which may decide the child's empiric regimen if there is resistance, and it tells me where to direct contact tracing and source-case treatment to break the transmission chain. [1]
References6ShowHide
- [1]Perez-Velez CM, Marais BJ Tuberculosis in children. N Engl J Med, 2012.PMID 22830465
- [2]Marais BJ, Gie RP, Schaaf HS, et al The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis, 2004.PMID 15141729
- [5]Kay AW, González Fernández L, Takwoingi Y, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev, 2020.PMID 32853411
- [6]Seddon JA, Tugume L, Solomons R, et al The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res, 2019.PMID 32118118
- [8]Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, et al The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J, 2011.PMID 21427627
- [7]Turkova A, Wills GH, Wobudeya E, et al. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. N Engl J Med, 2022.PMID 35263517